Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × patritumab deruxtecan × Clear all

NCT04699630 2025-12-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms